Slide 1: Slide 1
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains”forward-looking statements" that in volvesubstantial risksand uncertainties for purposes of the safe harbor within the meaning af Section 27Aof the Securities Act of 1933, asamended, and Section 21€ ofthe Securities Exch
Slide 3: Slide 3
Slide 4: Patient Demographics and Baseline Characteristics
Patient Demographics and Baseline Characteristics Well Balanced Patient Population Across Treatment Groups 30 mg IMU-838 45 mg IMU-838 Placebo Race white 100% 100% 100% Bex Male 44% 28% 33% Female 56% 72% 67% lage Mean (yrs.) 368 36.5 37.2 ke 40 yrs 62% 65% 65% 40 yrs 38% 35% 35% BMI Mean (ke/m?) 23
Slide 5: Liver Events
Liver Events Liver Enzyme Elevations Liver Enzyme Elevations 30 mg IMU-838 | 45 mg IMU-838 Placebo Number of Patients m1 69 69 Evaluated AIT or AST >5xULN 1 (1.4%) 3 (4.3%) 2 (2.9%) ALT or AST >10xULN 0 (0%) 1 (1.4%) 1 (1.4%) AIT or AST >15xULN 0 (0%) 0 (0%) 0 (0%) Liver enzyme elevations above cert
Slide 6: Liver Investigations
6 Liver Investigations No Generalized Effect on ALT or Total Bilirubin 500-4 ALT (GPT) [UL] i “1 ghd hisdid Sd4ads Bo 30 mg IMU-838 45 mg IMU-838 Treatment group Placebo (Wisk m-Day0 Wi Day? m Weeks Gi Week 12 Bi Week 16 @Week24] ALT: alanine arinetransferase Bilirubin total {mg/dL} 1 Treatment grou
Slide 7: Hematology Analysis
Hematology Analysis IMU-838 Does Not Reduce Blood Cell Counts Leukocytes Monocytes Absolute Counts u Eymbhesytes u (109 Cells/L) 30mg 45 mg 30 mg 45 mg 30 mg 45 mg IMU-838 | IMU-838 | IMU-838 | IMU-838 | IMU-838 | IMU-838 6.39 6.87 1.89 1.87 0.47 si Bersling (1.90) (2.05) (0.66) (0.52) (0.14) (0.18)
Slide 8: Neutrophils and Leukocytes: Hematology Analysis
Neutrophils abs, 10E9/L) Hematology Analysis No Generalized Effect on Neutrophils or Leucocytes Count ‘i ta (Wisk Day0 Day? w Wook © Wook 12 G Week 18 w Week24] (Vist Day0 Day? wm Wook © Week 12 © Week 16 @ Week24] IMU-838 treatment does not havea generalized effect on hematology laboratory values,
Slide 9: Hy's Law Assessment for Drug-Induced Liver Injury
3 Hy’s Law Assessment for Drug-Induced Liver Injury No Hy’s Law Cases for Either ALT or AST 10 | Hvperbitrabineria laxuLN y's Law Range Peak BIL! [xULN] an cot -{ Normal range Treatment group 145 mg IMU-838| © 30 mg IMU838 Jo Placebo [SxULN. oot on Peak ALT [xULN] 10 Peak BIL! [xULN] 10 on oot Hyper
Slide 10: Absence of Hepatotoxicity Signals
Absence of Hepatotoxicity Signals Hy’s Law Assessment for Drug-Induced Liver Injury Absence of Hepatotoxicity Signals and Other Relevant Adverse Events Leading to Discontinuations Differentiates Against Other Available Oral RRMS Medications. D Hy’s Law Assessment (ALT) Liver Enzyme Elevations 10 | H
Slide 11: Urine Sediment Analysis
Urine Sediment Analysis No Generalized Effect Regarding Hematuria 100 4 °° ° ° ° oo°0 95-4 504 ° ° ° ° F 44 There is no 7 405 trend for g 8 increased 3 30-4 . 3 hematuria (as ¢ 2-4 ° ° °° ° z 2 204 measured by 5 44 urine sediment) 104 cco o0000 °° ° during IMU-838 ° 54 e2020000 e@0000 e treatment of
Slide 12: Serum Uric Acid
Serum Uric Acid No Generalized Change from Baseline oo, » eo} ° 84 ° 6 . 2% ‘ °° ° ° 8 ° 3 6 There is no E . 3 generalized 2 effect on serum > ad uric acid during IMU-838 treatment. 24 30mg Muse 45mg imu3e Placebo Treatment group [Visit @ Day 0 @ Day7 @ Week6 @ Week 12 @ Week 18 @ Week 24] 12 | ©lmm
Slide 13: Immunic, Inc.
Immunic, Inc. 1200 Avenue of the Americas, Suite 200 New York, NY 10036, USA i) www.imux.com 13 | @tmmunic, inc. | Nowos/2020 Head of IR & Communications Phone: +49 89 2080 477 09 Email: ir@imux.com & Immunic